Literature DB >> 15108987

Synergistic antinociceptive effect of amitriptyline and morphine in the rat orofacial formalin test.

Philippe Luccarini1, Laurent Perrier, Céline Dégoulange, Anne-Marie Gaydier, Radhouane Dallel.   

Abstract

BACKGROUND: Combination therapy is often used to increase the clinical utility of analgesic agents. The coadministration of two compounds may achieve analgesia at doses lower than those required for either compound alone, leading to enhanced pain relief and reduction of adverse effects. Herein, the authors describe the effect of coadministration of morphine and amitriptyline on cutaneous orofacial inflammatory pain in rats.
METHODS: Amitriptyline, morphine, or the combination of amitriptyline and morphine was administered systemically to rats, and antinociceptive effects were determined by means of the rat orofacial formalin test. Isobolographic analysis was used to define the nature of the interactions between morphine and amitriptyline.
RESULTS: Amitriptyline as well as morphine produced a dose-related inhibition in the first phase and the second phase of rubbing activity. ED50 values against rubbing behavior were 14.6 mg/kg (95% confidence interval, 10.2-33.5 mg/kg) and 1.3 mg/kg (95% confidence interval, 1.0-1.7 mg/kg) for amitriptyline and morphine, respectively. Combinations of increasing fractional increments of amitriptyline and morphine ED50 doses produced a synergistic effect against rubbing behavior, as revealed by isobolographic analysis.
CONCLUSIONS: The current study suggests that systemic amitriptyline and morphine synergistically inhibit cutaneous orofacial inflammatory pain in rats.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15108987     DOI: 10.1097/00000542-200403000-00033

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats.

Authors:  Ercan Ozdemir; Sinan Gursoy; Ihsan Bagcivan
Journal:  J Physiol Sci       Date:  2012-04-29       Impact factor: 2.781

2.  Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective.

Authors:  Emily O Dumas; Gary M Pollack
Journal:  AAPS J       Date:  2008-11-07       Impact factor: 4.009

3.  A greater role for the norepinephrine transporter than the serotonin transporter in murine nociception.

Authors:  F S Hall; J M Schwarzbaum; M T G Perona; J S Templin; M G Caron; K-P Lesch; D L Murphy; G R Uhl
Journal:  Neuroscience       Date:  2010-12-01       Impact factor: 3.590

4.  Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?

Authors:  Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis
Journal:  Support Care Cancer       Date:  2014-08-29       Impact factor: 3.603

5.  Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.

Authors:  Taylor Harrison; Sachiko Miyahara; Anthony Lee; Scott Evans; Barbara Bastow; David Simpson; Ian Gilron; Robert Dworkin; Eric S Daar; Linda Wieclaw; David B Clifford
Journal:  Pain Med       Date:  2013-04-08       Impact factor: 3.750

6.  Behavioral testing in rodent models of orofacial neuropathic and inflammatory pain.

Authors:  Agnieszka Krzyzanowska; Carlos Avendaño
Journal:  Brain Behav       Date:  2012-08-15       Impact factor: 2.708

7.  Effect of pilocarpine on the formalin-induced orofacial pain in rats.

Authors:  Esmaeal Tamaddonfard; Amir Erfanparast; Emad Khalilzadeh
Journal:  Vet Res Forum       Date:  2012       Impact factor: 1.054

8.  Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome.

Authors:  Anna Rickli; Evangelia Liakoni; Marius C Hoener; Matthias E Liechti
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.